Mavatar Establishes U.S. Presence and Prepares Launch of Mavatar Discovery

Stockholm, 2025-06-13

Swedish healthtech company Mavatar, a pioneer in AI- and data-driven solutions for precision medicine, today announced the opening of its first U.S. office and the upcoming commercial launch of its platform Mavatar Discovery. These developments mark a key step in the company’s international expansion and its mission to revolutionize global healthcare.

In response to strong global demand for AI-based and data-driven precision medicine solutions, Mavatar completed its latest funding round in late 2024. The company has since opened an office in Delaware, USA, initiated recruitment of new talent, and is currently in discussions around additional capital and strategic partnerships.

Mavatar is now preparing the full-scale launch of Mavatar Discovery, a platform designed to help researchers and life science companies accelerate the understanding of disease biology, identify novel biomarkers, and speed up drug development. Following a successful closed beta period, the company is now opening the platform to early access opportunities.

Built on over 20 years of research and advanced AI technology, Mavatar Discovery can integrate and interpret vast amounts of transcriptomic data and turn them into actionable insights — in just minutes. Previously, this type of analysis could take months.

“The full launch of Mavatar Discovery in September will be a major milestone for us,” said Johan Juhlin, CEO and co-founder of Mavatar. “By making advanced analysis more accessible, researchers can focus where it really matters – on improving precision and finding the right treatments faster. Our U.S. expansion is also a strategically important step. We now look forward to growing, further developing our platforms, and building strong partnerships to support our continued growth.”

Digital Twins

Mavatar Discovery is powered by the company’s proprietary Deep Integrated Network Analysis (DINA) framework, which integrates and analyzes large volumes of biomedical data from diverse sources. Discovery unlocks entirely new possibilities in precision medicine and drug development by enabling better-informed decisions and drastically reducing the time needed to discover and develop new treatments.

"Mavatar Discovery gave us the ability to explore disease mechanisms and cross-disease patterns in a way we’ve never seen before. The platform’s 100% data-driven insights are not only novel - they’re biologically meaningful", said Walter Fischer, PhD, Associate Professor and CEO of GutFeeling Labs, one of the companies that participated in the closed beta testing of Discovery.

In 2026, Mavatar will launch a second platform, Mavatar Precision, a clinical decision support tool that enables tailored treatment recommendations based on each patient’s unique biology. By analyzing biomarker data from a simple blood sample, the platform can match a patient to a digital twin – a virtual model that mirrors the molecular profile of the patient’s disease. In this model, different treatment options are simulated to identify which therapy is likely to be the best one. The result: more accurate treatments from day one – before any medication is prescribed.

Mavatar will be present at the BIO International Convention 2025 in Boston June 16–19, the world’s largest biotechnology event, gathering over 20,000 participants from across the globe.